



## Treatment of Secondary Immune Mediated Hemolytic Anaemia of Dogs in Chennai, Tamil Nadu

Chopel G. Lachungpa<sup>1</sup>, D. Chandrasekaran<sup>2\*</sup>, M.B. Thilagar<sup>3</sup> and T.M.A Senthil Kumar<sup>4</sup>

<sup>1</sup>Department of Veterinary Clinical Medicine, Madras Veterinary College, Tamil Nadu Veterinary and Animal Sciences University, Chennai, Tamil Nadu, INDIA

<sup>2</sup>Department of Clinics, Madras Veterinary College, Tamil Nadu Veterinary and Animal Sciences University, Chennai, Tamil Nadu, INDIA

<sup>3</sup>Department of Veterinary Clinical Medicine, Madras Veterinary College, Tamil Nadu Veterinary and Animal Sciences University, Chennai, Tamil Nadu, INDIA

<sup>4</sup>Department of Animal Biotechnology, Madras Veterinary College, Tamil Nadu Veterinary and Animal Sciences University, Chennai, Tamil Nadu, INDIA

\*Corresponding author: D Chandrasekaran; E-mail: drchandrus73@gmail.com

Received: 04 June, 2020

Revised: 14 July, 2020

Accepted: 26 July, 2020

### ABSTRACT

Immune-mediated hemolytic anemia (IMHA) is the most common autoimmune disease in dogs. This study was conducted to evaluate prednisolone and azathioprine therapeutic protocols for the management of secondary IMHA in dogs. The anaemic dogs brought with clinical signs such as pale or icteric mucous membranes were screened for IMHA by saline agglutination and spherocyte count and confirmed by flow cytometry. The positive cases were further subjected to haematology, biochemistry, coagulation profile, MAT and polymerase chain reaction (PCR) for the diagnosis of underlying secondary causes like *Babesia* spp, *Ehrlichia canis* and *Leptospira* spp (secondary IMHA). Thirty two cases were positive for IMHA, out of which thirteen cases were primary (Idiopathic) IMHA (17.3 %) and remaining nineteen cases were secondary IMHA (82.7 %) due to underlying causes such as *Babesia gibsoni* (13), *Ehrlichia canis* (3) and *Leptospira* spp. (3) respectively. Immunosuppressive therapy with prednisolone and prednisolone in combination with azathioprine and specific therapy of etiological agent with supportive therapy was used. Significant increase in Hb, PCV, RBC and thrombocyte count, significant decrease in leucocyte, neutrophil, monocyte and total protein and significant increase in ALT activity was recorded after therapy. There was an apparent clinical improvement in all the dogs which survived till day 28 days, with significant improvement in hemato-biochemical profiles. Prednisolone was found to be effective in the management of canine secondary IMHA than prednisolone combined with azathioprine.

### HIGHLIGHTS

- Secondary Immune mediated hemolytic anemia – Immunosuppressive therapy - Prednisolone, Prednisolone + Azathioprine.
- Prednisolone – Effective in management of canine secondary IMHA.

**Keywords:** Dog, Secondary IMHA, Treatment, Prednisolone, Azathioprine

Immune-mediated haemolytic anaemia (IMHA) was a type II hypersensitivity reaction in which antibodies (mainly IgG and IgM) were produced against normal RBCs (primary IMHA) or against RBCs in which surface antigens were altered through interaction with secondary causes such as drugs, infectious diseases and neoplasia (secondary IMHA) (McAlees, 2010).

Secondary IMHA is caused by an immunologic response to nonself antigens that have modified or are associated

**How to cite this article:** Lachungpa, C.G., Chandrasekaran, D., Thilagar, M.B. and Senthil Kumar T.M.A (2020). Treatment of secondary immune mediated hemolytic anaemia of dogs in Chennai, Tamil Nadu. *J. Anim. Res.*, 10(4): 535-541.

**Source of Support:** None; **Conflict of Interest:** None



with normal RBC membranes. Secondary IMHA can be caused by a number of underlying processes. Affected RBCs may become infected by pathogens or coated with foreign antigen. Documented or hypothesized causes of secondary IMHA include bacterial, viral, rickettsial, parasitic, protozoan and neoplastic disorders (Giger, 2005).

Immunomodulation is the mainstay of treatment of IMHA, with the aim of decreasing erythrophagocytosis and suppressing immunoglobulin production and can be combined with whole blood or packed red cell transfusions and anticoagulation (Balch and Mackin, 2007).

McCullough (2003) and Weinkle *et al.* (2005) reported that prednisone typically dosed @ 2 mg/kg PO q12–24h, once remission had been maintained for 1 to 2 weeks, and then the dose could be reduced by 25 to 50 per cent every 2 to 4 weeks. Treatment could generally be stopped once the dose had been reduced to 0.25 to 0.5 mg/kg PO q48h.

McCullough (2003) reported azathioprine used in dogs at a dose of 2 mg/kg PO q24h. The dose was often given on alternate days when prednisone therapy was decreased to every other day. Balch and Mackin (2007) reported that azathioprine, a purine analogue anti metabolite that preferentially suppresses T-cell function, frequently used as an additional immunosuppressive agent in dogs with severe IMHA.

Hence, the present study was undertaken with the objective to evaluate prednisolone and azathioprine therapeutic protocols for the management of secondary IMHA in dogs.

## MATERIALS AND METHODS

### Selection of animals and sampling

Seventy five anemic dogs were presented to the Small Animals Out-Patient Unit of Madras Veterinary teaching Hospital and Critical Care Unit of the Department of Veterinary Clinical Medicine, Madras Veterinary College, Chennai during a period of 1 year from July 2016 to June 2017. An individual history of those dogs with pale or icteric mucous membranes were screened for IMHA by saline agglutination test, spherocyte count and confirmed by flow cytometry.

Thirty-two dogs positive by flow cytometry were selected

for the study. The saline agglutination test was performed by mixing a drop of whole blood collected in EDTA vacutainer with drop of saline on a glass slide. Microscopic agglutination test was performed with a saline dilution on a glass slide (one drop of blood to two drops of saline) and inspected under light microscope. The positive result was manifested by clumping of red blood cells (Balch and Mackin, 2007). An air dried thin blood smear was made from capillary blood obtained from the anterior edge of the hairless ventral surface of the ear, stained with Leishman-Giemsa stain and examined microscopically for *Babesia* species and *Ehrlichia canis* organism, differential leucocyte count, spherocyte count and blood picture analysis.

### Flow cytometer

Whole blood samples were analyzed by a flow cytometer as per the procedure of Kucinskiene *et al.* (2005). The IMHA fluochrome stained RBCs were acquired using MoFlow XDP flowcytometry (Beckman Coulter, USA) and data were analyzed using the summit software.

### Multiplex polymerase chain reaction (PCR)

DNA isolation kit (QIAamp DNA Mini Kit®, Qiagen) was used for the extraction of parasite DNA from 200µl of blood collected in EDTA vacutainers according to the manufacturer's instructions. Genomic DNA isolated from the whole blood of healthy dog was used as a negative control.

Multiplex PCR for the amplification of the 16s rRNA gene fragment of molecular length 619 bp in genus *Babesia* and VirB9 of *E. canis* with a molecular length 380 bp was employed following the procedure of Kledmanee *et al.*, (2009). Nested PCR for the amplification of the 16s rRNA gene fragment of *E. canis* was employed following the procedure of Rajagopal *et al.* (2009). Thermocycling consisted of initial denaturation step of 15 min at 94°C followed by 30 cycles of 45 sec at 94°C, 45 sec at 65°C, and 90 sec at 72°C with a final extension step of 10 min at 72°C. The amplicons were separated by electrophoresis in 1.5% agarose gel in 40 mM Tris-acetic acetate of pH 8.4, 1 mM EDTA, stained with ethidium bromide (0.5 µg/ml) and visualized under UV light.

### Microscopic agglutination test (MAT)

A battery of live leptospira serovars (*L. australis*, *L. autumnalis*, *L. ballum*, *L. bataviae*, *L. canicola*, *L. grippityphosa*, *L. hebdomadis*, *L. icterohaemorrhagiae*, *L. javanica*, *L. pomona* and *L. pyrogenes*) were employed. The antigen antibody reaction / agglutination observed at > 1: 200 serum dilutions were considered positive.

Positive samples for hemoprotozoan parasite like *Babesia spp* and *Ehrlichia spp* screened by multiplex PCR and leptospirosis by MAT were included for the study. The results are expressed as mean±SE. Data are classified with descriptive statistics and P values <0.05 are considered statistically significant. Data analysis was performed with the SPSS 20.

### TREATMENT PROTOCOL

Two groups viz. I and II were formed with each group comprising of 7 and 6 dogs of different breed, either sex and varying age. The drugs indicated for secondary IMHA (*Babesia gibsoni*) were given in different combination in two groups. In Group I (n=7), treatment of underlying causes with prednisolone. Combination therapy with clindamycin (Bioclan, Savavet, Sava healthcare Ltd. 25 mg, 150 mg and 300 mg) @ 25 mg / kg body weight *per os* BID, metronidazole (Flagyl, AHPL, India, 200 mg and 400 mg) @ 15 / kg body weight *per os* BID and doxycycline (Doxypet, Savavet, Sava healthcare Ltd., 200 mg) @ 5 mg / kg body weight *per os*. BID for 28 days as per Suzuki *et al.* (2007). Prednisolone was given at the rate of 2 mg / kg body weight I/M or *per os* BID for 5 days followed by 1 mg / kg body weight *per os* BID for next 5 days *per os*. The drug was tapered to 0.5 mg/kg body weight *per os* SID for next 5 days. Whereas in Group II (n=6), treatment of underlying causes with Prednisolone + Azathioprine. Combination therapy with clindamycin @ 25 mg / kg body weight *per os* BID, metronidazole @ 15 / kg body weight *per os* BID and doxycycline @ 10 mg / kg body weight *per os* BID for 28 days as per Suzuki *et al.* (2007). Azathioprine @ 1 mg/kg body weight *per os* BID for first 5 days followed by 0.5 mg / kg body weight *per os* BID for next 5 days. The drug was tapered to 0.5 mg/kg body weight *per os* BID for another 5 days. Prednisolone @ 2 mg / kg body weight *per os* BID for 5 days followed by 1 mg / kg body weight *per os* BID for next 5 days. The drug was tapered to 0.5 mg / kg body weight *per os* SID for another 5 days.

### Supportive therapy

The dogs with PCV less than 10 per cent or those dogs hemodynamically unstable were given fresh whole blood transfusion @ 12-20 ml/kg body weight. The dogs were administered with multiple electrolytes, dextrose injection and lactated ringer's solution @ 10ml/ kg body weight. The dog with anemia (PCV<20 per cent) were prescribed oral haematinics (aRBC syrup) and Thrombup syrup. Dogs with vomiting were injected with inj. Ondansetron I/V (Emeset, 2 ml, Cipla Pharma Ltd.) @ 0.05 mg/kg body weight and inj. Ranitidine (Ultidec, SPM drug Pvt. Ltd.) @ 1mg/kg I/M for 3-5 days.

### Post treatment assessment

Post treatment assessment was carried out after 14<sup>th</sup> and 28<sup>th</sup> day post treatment, based on haematological, biochemical and coagulation parameters and clinical improvement. Whole blood and serum samples were collected on before treatment on 0 day and post treatment assessment was done after 14<sup>th</sup> day and 28<sup>th</sup> day based on haematological, biochemical and coagulation parameters and clinical improvement.

### RESULTS AND DISCUSSION

Haematological, biochemical and coagulation parameters were recorded before treatment (0 day) and after treatment viz., 14<sup>th</sup> day and 28<sup>th</sup> day in secondary IMHA. The quantitative data were subjected to One-Way Anova and independent sample t-test.

In thirteen secondary IMHA dogs, seven dogs received immunosuppressive dose of prednisolone (P Protocol) and six dogs received prednisolone combined with azathioprine (AP Protocol). In secondary IMHA, dogs treated with prednisolone, there was apparent clinical recovery on day 14<sup>th</sup> and 28<sup>th</sup> day after initiation of treatment. In all the dogs which survived, there was a significant increase in the means of Hb, RBC, PCV, MCHC and platelets and decrease in mean WBC and mean neutrophil (Table 1 and 2). But there was no significant difference in means of MCV, MCH, lymphocyte, monocyte, eosinophil, PT and APTT.

Mean activity levels of ALT, total bilirubin and direct bilirubin were significantly reduced on 14<sup>th</sup> and 28<sup>th</sup> day after treatment with prednisolone. Mean of glucose was

**Table 1:** Effect of different treatments on haemogram in secondary IMHA (n = 13)

Parameters	Prednisolone (n=7)				Prednisolone + Azathioprine (n=6)			
	Day 0	14 <sup>th</sup> day	28 <sup>th</sup> day	F-Value	Day 0	14 <sup>th</sup> day	28 <sup>th</sup> day	F-Value
Hb (g/dL)	4.14±0.66 <sup>a</sup>	8.98±0.99 <sup>b</sup>	12.02±0.31 <sup>c</sup>	28.43**	4.30±0.50 <sup>a</sup>	6.18±0.82 <sup>a</sup>	8.53±0.35 <sup>b</sup>	7.67**
RBC (mill/μL)	3.29±0.97 <sup>a</sup>	4.80±0.58 <sup>a</sup>	6.80±0.85 <sup>b</sup>	15.93**	2.29±0.23 <sup>a</sup>	2.03±0.29 <sup>a</sup>	5.36 ±0.48 <sup>b</sup>	0.79*
HCT (%)	13.55±3.21 <sup>a</sup>	28.15±3.04 <sup>b</sup>	35.76±0.89 <sup>b</sup>	23.76**	19.08±1.13	22.33±4.56	26.60±5.80	3.93 <sup>NS</sup>
MCV (fL)	66.57±3.02	59.87±5.57	69.61±8.22	0.78 <sup>NS</sup>	58.87±3.44	53.45±2.90	43.61±13.78	1.59 <sup>NS</sup>
MCHC (g/dL)	30.37±0.54 <sup>a</sup>	32.01±0.75 <sup>a,b</sup>	33.66±0.93 <sup>b</sup>	5.11*	22.99±3.18	31.48±4.94	3634±9.86	1.53 <sup>NS</sup>
MCH (pg)	20.18±0.83	18.98±1.32	23.19±2.23	2.07 <sup>NS</sup>	13.67±2.27	16.94±3.11	19.16±1.90	0.55 <sup>NS</sup>

Mean bearing same manuscript in the row do not differ significantly; \*\* - Statistically highly significant (P≤0.01) \* - Statistically significant (P>0.05) <sup>NS</sup> – Non significant.

**Table 2:** Effect of different treatments on leucogram and coagulation profile in secondary IMHA (*Babesia gibsoni*) (n=13)

Parameters	Prednisolone (n=7)				Prednisolone + Azathioprine (n=6)			
	Day 0	14 <sup>th</sup> day	28 <sup>th</sup> day	F-Value	Day 0	14 <sup>th</sup> day	28 <sup>th</sup> day	F-Value
WBC (/ μL)	21671.43 ± 3416.11 <sup>a</sup>	11983.33 ± 1443.70 <sup>b</sup>	8520 ± 1243.14 <sup>b</sup>	7.39**	21033.33 ± 3402.02	15666.67 ± 2654.13	12333.33 ± 881.91	1.84**
Neutrophil (%)	84 ± 1.90 <sup>a</sup>	78.33 ± 2.70 <sup>b</sup>	73.60 ± 0.98 <sup>b</sup>	6.07*	73.67 ± 0.84 <sup>a</sup>	77.83 ± 0.71 <sup>b</sup>	73.67 ± 1.45 <sup>a</sup>	4.88*
Lymphocyte (%)	12.57 ± 1.67	17.17 ± 1.44	16.80 ± 1.44	2.85 <sup>NS</sup>	16.33 ± 0.71	15.33 ± 1.47	17.67 ± 1.76	0.66 <sup>NS</sup>
Monocyte (%)	4.14±0.26	4.33±0.55	4.20±0.66	0.43 <sup>NS</sup>	8.33±1.08	6.67±1.08	5±00	1.91 <sup>NS</sup>
Eosinophil (%)	0.57 ± 0.36	0.17 ± 0.16	0.20 ± 0.20	0.66 <sup>NS</sup>	1.50±0.34	1.40 ± 0.40	0.67 ± 0.33	1.11 <sup>NS</sup>
Platelet (10 <sup>3</sup> /cmm)	50142.86 ± 6688.40 <sup>a</sup>	131566.67 ± 2258.80 <sup>b</sup>	249800 ± 36295.17 <sup>c</sup>	20.23**	71166.67 ± 12365.04 <sup>a</sup>	123333.33 ± 18282.35 <sup>a,b</sup>	186333.33 ± 14497.21 <sup>b</sup>	10.28**
PT (sec)	40.43±10.07	19.33 ± 2.82	17.20±5.43	2.58 <sup>NS</sup>	41.33±1.96 <sup>a</sup>	18.0±2.3 <sup>b</sup>	10 ± 1.0 <sup>c</sup>	53.49**
APTT(sec)	42.74±7.57	29.33 ± 5.30	18.80 ± 2.41	3.05 <sup>NS</sup>	61.91 ± 13.51	38.83 ± 7.58 <sup>a</sup>	17.00 ± 3.00	3.5 <sup>NS</sup>

Mean bearing same manuscript in the row do not differ significantly; \*\* - Statistically highly significant (P≤0.01) \* - Statistically significant (P>0.05) <sup>NS</sup> – Non significant.

increased on 28<sup>th</sup> day after treatment with prednisolone. However, there was no significant difference in means of BUN, creatinine, total protein, albumin, globulin, A:G ratio and ALP activity.

In prednisolone and azathioprine combined treatment group there was a significant increase in the means of Hb, RBC and platelet. There was a significant decrease in mean of WBC, neutrophil and PT and Blood urea nitrogen (BUN) post treatment. But there was no significant difference in means of MCV, MCH, MCHC, lymphocyte, monocyte, and eosinophil and APTT. However, there was significantly increased activities of ALP and ALT after treatment (Table 3).

Mean of Blood urea nitrogen (BUN) was significantly reduced on 14<sup>th</sup> and 28<sup>th</sup> day after treatment with prednisolone and azathioprine combination. There was significant increase in mean activity levels of ALT and

ALP but there was no significance difference in means of total bilirubin, direct bilirubin, creatinine, total protein, albumin, globulin and A:G ratio.

When compared between treatments of prednisolone group (P protocol) and prednisolone combination with azathioprine group (AP Protocol) on 14<sup>th</sup> and 28<sup>th</sup> day after treatment as shown in Table 4, Table 5 and Table 6. The mean of Hb and RBC on 28<sup>th</sup> day was significantly higher and eosinophil on 14<sup>th</sup> day was significantly lower in the group of dogs treated with prednisolone when compared to prednisolone+ azathioprine group. The means of remaining haematological and coagulation parameter were not significant.

Balch and Mackin (2007) reported prednisone single-agent glucocorticoid therapy were the mainstay and first line of treatment for IMHA for many patients and effective. The improvement might be due to reduced erythrophagocytosis

**Table 3:** Effect of different treatments on serum biochemistry in secondary IMHA (*Babesia gibsoni*) (n=13)

Parameters	Prednisolone (n=7)				Prednisolone + Azathioprine (n=6)			
	Day 0	14 <sup>th</sup> day	28 <sup>th</sup> day	F-Value	Day 0	14 <sup>th</sup> day	28 <sup>th</sup> day	F-Value
BUN (mg/dL)	52.39 ± 9.29	36.50 ± 5.30	25.80 ± 2.80	3.48 <sup>NS</sup>	55.50 ± 7.10 <sup>a</sup>	37.10 ± 2.25 <sup>ab</sup>	29.33 ± 6.96 <sup>b</sup>	5.22*
Cr (mg/dL)	1.42 ± 0.48	0.99 ± 0.22	0.69 ± 0.07	1.06 <sup>NS</sup>	1.54 ± 0.38	1.78 ± 0.49	1.05 ± 0.16	0.45 <sup>NS</sup>
TP (g/dL)	6.85 ± 0.26	6.80 ± 0.55	6.92 ± 0.29	0.92 <sup>NS</sup>	6.98 ± 0.32	6.61 ± 0.16	7.03 ± 0.06	0.78 <sup>NS</sup>
Albumin (g/dL)	2.21 ± 0.13	2.78 ± 0.25	2.52 ± 0.11	3.71 <sup>NS</sup>	2.21 ± 0.13	2.43 ± 0.14	2.56 ± 0.14	1.32 <sup>NS</sup>
Globulin (g/dL)	4.20 ± 0.49	4.53 ± 0.49	4.40 ± 0.28	0.14 <sup>NS</sup>	4.76 ± 0.32	4.18 ± 0.25	4.46 ± 0.20	1.14 <sup>NS</sup>
Albumin:Globulin	0.59 ± 0.13	0.57 ± 0.13	0.58 ± 0.05	0.04 <sup>NS</sup>	0.47 ± 0.48	0.60 ± 0.7	0.57 ± 0.05	1.22 <sup>NS</sup>
ALT (IU/L)	252.00 ± 38.80 <sup>a</sup>	127.50 ± 43.16 <sup>b</sup>	91.40 ± 33.75 <sup>b</sup>	4.67*	74.67 ± 32.71	68.00 ± 14.53	266.83 ± 47.75	14.01**
ALP (IU/L)	387.29 ± 60.16	330.83 ± 72.9	473.40 ± 150.53	0.54 <sup>NS</sup>	166.17.0 ± 29.13	308.50 ± 79.08	563 ± 85.32	8.40**
T.bilirubin (IU/L)	2.33 ± 0.34 <sup>a</sup>	0.76 ± 0.18 <sup>b</sup>	0.56 ± 0.08 <sup>b</sup>	14.2*	1.46 ± 0.29	0.88 ± 0.20	0.62 ± 0.14	2.62 <sup>NS</sup>
D.bilirubin (IU/L)	1.74 ± 0.20 <sup>a</sup>	0.54 ± 0.14 <sup>b</sup>	0.48 ± 0.05 <sup>b</sup>	19.53*	1.45 ± 0.21	0.87 ± 0.26	0.65 ± 0.04	2.75 <sup>NS</sup>

Mean bearing same manuscript in the row do not differ significantly; \*\* - Statistically highly significant (P≤0.01) \* - Statistically significant (P>0.05) <sup>NS</sup> - Non significant.

of opsonized RBC (Piek, 2011) or decreased production of antibodies (Barker *et al.*, 1992) by reducing lymphocytes in the circulation pool (Dowling, 1995).

**Table 4:** Efficacy of different treatments on haemogram in secondary IMHA (*Babesia gibsoni*) (Comparison in between groups of treatment) (n=13)

Parameters	t-test value between group (Day14)	t-test value between group (Day28)
Hb (g/dL)	2.16 <sup>NS</sup>	7.05**
RBC(mill/μL)	0.45 <sup>NS</sup>	1.37*
HCT (%)	1.04 <sup>NS</sup>	2.08 <sup>NS</sup>
MCV (fL)	1.02 <sup>NS</sup>	1.74 <sup>NS</sup>
MCHC(g/dL)	0.10 <sup>NS</sup>	0.37 <sup>NS</sup>
MCH (pg)	0.60 <sup>NS</sup>	3.04 <sup>NS</sup>

NS -Non significant, \*\* - Statistically highly significant (P≤0.01), \* - Statistically significant (P < 0.05).

The mean of BUN on 14<sup>th</sup> day of treatment was significantly lower in prednisolone treated group compared to prednisolone combination with azathioprine group. Mean of ALT and ALP was significantly higher in prednisolone + azathioprine group as compared to prednisolone treated group on 28<sup>th</sup> day post treatment. Mean activities of ALP was significantly higher in prednisolone group as compared to prednisolone + azathioprine treated group

on 14<sup>th</sup> day post treatment. Weinkle *et al.* (2005) and Mason *et al.* (2003) stated good response or an improved overall prognosis in patients receiving the drug. Rinkardt and Kruth (1996), Whitley and Day (2011) reported immunosuppressive action was delayed for several weeks after beginning therapy. The idiosyncratic occurrence of myelosuppression and hepatotoxicity can present a monitoring challenge in IMHA dogs whose alkaline phosphatase is likely increased because of glucocorticoid therapy. Wang *et al.* (2013) reported adverse events including significantly increased ALT, vomiting and diarrhoea in dogs treated with azathioprine.

**Table 5:** Efficacy of different treatments on leucogram and coagulation profile in secondary IMHA (*Babesia gibsoni*) (Comparison in between groups of treatment)

Parameters	t-test value between group (Day14)	t-test value between group (Day28)
WBC (/ μL)	1.21 <sup>NS</sup>	2.14 <sup>NS</sup>
Neutrophil (%)	0.16 <sup>NS</sup>	0.40 <sup>NS</sup>
Lymphocyte (%)	0.88 <sup>NS</sup>	0.37 <sup>NS</sup>
Monocyte (%)	1.91 <sup>NS</sup>	0.95 <sup>NS</sup>
Eosinophil (%)	3.04*	1.29 <sup>NS</sup>
Platelet (10 <sup>3</sup> /cmm)	0.28 <sup>NS</sup>	1.28 <sup>NS</sup>
PT (sec)	0.36 <sup>NS</sup>	0.98 <sup>NS</sup>
APTT(sec)	1.02 <sup>NS</sup>	0.46 <sup>NS</sup>

NS - Non significant, \* - Statistically significant (P < 0.05).

**Table 6:** Efficacy of different treatments on serum biochemistry in secondary IMHA (*Babesia gibsoni*) (Comparison in between groups of treatment)

Parameters	t-test value between group (Day 14)	t-test value between group (Day 28)
BUN(mg/dL)	0.32*	0.56 <sup>NS</sup>
Cr (mg/dL)	1.40 <sup>NS</sup>	2.29 <sup>NS</sup>
TP (g/dL)	0.75 <sup>NS</sup>	0.28 <sup>NS</sup>
Albumin (g/dL)	1.25 <sup>NS</sup>	0.24 <sup>NS</sup>
Globulin (g/dL)	0.62 <sup>NS</sup>	0.16 <sup>NS</sup>
Albumin: Globulin	0.16 <sup>NS</sup>	0.06 <sup>NS</sup>
ALT (IU/L)	1.00 <sup>NS</sup>	3.14**
ALP (IU/L)	2.69*	4.71**
T.bilirubin (IU/L)	0.42 <sup>NS</sup>	0.36 <sup>NS</sup>
D.bilirubin (IU/L)	1.07 <sup>NS</sup>	2.20 <sup>NS</sup>

NS - Non significant, \*\* - Statistically highly significant (P≤0.01), \* - Statistically significant (P < 0.05).

### Treatment outcome/response

Out of seven dogs received prednisolone treatment (P Protocol) one dog died on 1<sup>st</sup> week and remaining six dogs recovered after four weeks of treatment.

Out of six dogs received prednisolone + azathioprine treatment (AP Protocol) two dogs died on 1<sup>st</sup> week and remaining four dogs recovered after four weeks of treatment.

In the present study, mortality in secondary IMHA was 23.1 per cent. In secondary IMHA prednisolone and prednisolone + azathioprine treatment group mortality was 14.3 per cent and 33.33 per cent respectively.

The mortality in the present study was 23.1 per cent (secondary IMHA), similar rate of mortality (20 to 33 per cent) was observed by Jackson and Kruth (1985), Klag *et al.* (1993) and Scott-Moncrieff *et al.* (2001). Mortality is mostly in the first 2 weeks of diagnosis (Piek, 2011). Similar observation was recorded in present study. Mortality in IMHA dogs might be due to thromboembolism (Scott – Moncrieff *et al.*, 2001), tissue hypoxia and subsequent necrosis due to severe anaemia, liver and kidney failure, inflammation and DIC (McCanus and Craig, 2001 and Piek, 2011). Necropsy could not be performed in the present study due to the animal collapsed in the owner’s house, the exact reason for death was not identified.

### CONCLUSION

The anaemic dogs brought with clinical signs such as pale or icteric mucous membranes were screened for IMHA by saline agglutination and spherocyte count and confirmed by flow cytometry. The positive cases were further subjected to haematology, biochemistry, coagulation profile, MAT and polymerase chain reaction (PCR) for the diagnosis of underlying secondary causes like *Babesia spp*, *Ehrlichia canis* and *Leptospira spp* (secondary IMHA). Thirteen cases were secondary IMHA and immunosuppressive therapy with prednisolone and prednisolone in combination with azathioprine and specific therapy of etiological agent with supportive therapy was used. Significant increase in Hb, PCV, RBC and thrombocyte count, significant decrease in leucocyte, neutrophil, monocyte and total protein and significant increase in ALT activity was recorded after therapy. Prednisolone was found to be effective in the management of secondary IMHA than prednisolone combined with azathioprine.

### REFERENCES

- Balch, A. and Mackin, A. 2007. Canine immune-mediated hemolytic anemia: pathophysiology, clinical sign, and diagnosis. *Compend. Contin. Educ. Vet.*, **29**(4): 217-225.
- Barker, R.N., Gruffydd-Jones, T.J., Stokes, C.R. and Bourne, F.J. 1992. Autoimmune haemolysis in the dog: relationship between anaemia and the levels of red blood cell bound immunoglobulins and complement complement measured by an enzyme-linked antiglobulin test. *Vet. Immunol. Immunopathol.*, **34**: 1–20.
- Burgess, K., Moore, A. and Rand, W. 2000. Treatment of immune-mediated hemolytic anemia in dogs with Cyclophosphamide. *J. Vet. Intern. Med.*, **14**(4): 456-462.
- Dowling, P.M. 1995. Immunosuppressive drug therapy. *Can. Vet. J.*, **36**(12): 781-783.
- Giger, U. 2005. Regenerative anemias caused by blood loss or hemolysis. In: Ettinger SJ, Feldman EC (eds): *Textbook of Veterinary Internal Medicine*, 6<sup>th</sup> Edn., St Louis, Saunders, pp. 1886–1907.
- Jackson, M.L. and Kruth, S.A. 1985. Immune-mediated hemolytic anemia and thrombocytopenia in dogs: a retrospective study of 55 cases diagnosed from 1969 through 1983 at the western college of veterinary medicine. *Can. Vet. J. Res.*, **26**(8): 245-250.
- Klag, A., Giger, U. and Shofer, F. 1993. Idiopathic immune-mediated hemolytic anemia in dogs: 42 cases (1986– 1990). *J. Am. Vet. Med. Assoc.*, **202** (5): 783–788.

- Kledmanee, K., Suwanpakdee, S., Krajangwong, S., Chatsiriwech, J., Sukasai, P., Suwannachat, P., Sariya, L., Buddhironngawatr, R., Charoonrut, P. and Chaichoun, K. 2009. Development of multiplex polymerase chain reaction for detection of *Ehrlichia canis*, *Babesia* spp. and *Hepatozoan canis* in canine blood. *Southeast Asian T. Med. Public Health*, **40**(1): 35–39.
- Kucinskiene, G., Schuberth, H.J., Leibold, W.J. and Pieskus, J. 2005. Flow cytometric evaluation of bound IgG on erythrocytes of anaemic dogs. *Vet. J.*, **169**: 303–307.
- Mason, N., Duval, D., Shofer, F.S. and Giger, U. 2003. Cyclophosphamide exerts no beneficial effect over prednisone alone in the initial treatment of acute immune mediated hemolytic anemia in dogs: a randomized controlled clinical trial. *J. Vet. Intern. Med.*, **17**(2): 206–212.
- McAlees, T.J. 2010. Immune-mediated hemolytic anaemia in 110 dogs in Victoria, Australia. *Aust. Vet. J.*, **88**: 25–28.
- McManus, P. and Craig, L. 2001. Correlation between leukocytosis and necropsy finding in dogs with immune mediated hemolytic anemia: 34 cases (1994–1999). *JAVMA*, **218**(8): 1308–1313.
- Piek, C.J. 2011. Canine idiopathic immune-mediated hemolytic anemia: a review with recommendations for future research. *Vet. Q.*, **31**: 129–141.
- Rinkardt, N.E. and Kruth, S.A. 1996. Azathioprine-induced bone marrow toxicity in four dogs. *Can. Vet. J.*, **37**: 612–613.
- Scott-Moncrieff, J.C., Treadwell, N.G. and McCullough, S.M. 2001. Hemostatic abnormalities in dogs with primary immune-mediated hemolytic anemia. *J. Am. Anim. Hosp. Assoc.*, **37**: 220–227.
- Suzuki, K., Wakabayashi, H., Takahashi, M., Fukushima, K., Yabuki, K. and Endo, Y. 2007. A possible treatment strategy and clinical factors to estimate the treatment response in *Babesia gibsoni* infection. *J. Vet. Med. Sci.*, **69**(5): 563–568.
- Wang, A., Smith, J.R. and Creevy, K.E. 2013. Treatment of canine idiopathic immune mediated haemolytic anaemia with mycophenolate mofetil and glucocorticoids: 30 cases (2007 to 2011). *J. Small. Anim. Pract.*, **54**(8): 399–404.
- Weinkle, T.K., Center, S.A., Randolph, J.F., Warner, K.L., Barr, S.C. and Erb, H.N. 2005. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993–2002). *J. Am. Vet. Med. Assoc.*, **226**: 1869–1880.
- Whitley, N.T. and Day, M.J. 2011. Immunomodulatory drugs and their application to the management of canine immune-mediated disease. *J. Small. Anim. Pract.*, **52**(2): 70–85.

